(Published in Part II, Section 3, Sub-section (ii) of
the Gazette of India, Extraordinary)
Government of India
Ministry of Chemicals and Fertilizers
National Pharmaceutical Pricing Authority
New Delhi, the 16th April, 2010
ORDER
S.O. 875(E)- In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (6) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Biocon Ltd.
TABLE
Sl. Name of the Pack Existing Retail Price Equivalent
No. formulation Size Retail without MRP*
Price Excise Duty inclusive
Sales Tax /VAT of all
and Local Tax, if any taxes
(Rs.) (Rs.) (Rs.)
(1) (2) (3) (4) (5) (6)
“1. Recombinant Human Insulin inj. 10ml — 274.36 293.46
Insugen – R (Regular) Vial
Insulin Injection, Biphasic Isophane,
(Human Insulin rDNA origin)
Human Insulin ph. Eur., – 100 IU/ml
m-Cresol – 0.25% w/v
- Recombinant Human Insulin inj. 10ml — 274.44 293.54
Insugen – 50:50 Vial
Insulin inj., Biphasic Iso., (Human
Insulin rDNA origin)
Human Insulin ph. Eur., – 100 IU/ml
(Soluble Insulin 50 IU/ ML and Crystalline
Insulin 50 IU/ML
Metacresol – 0.16% w/v
Phenol – 0.065% w/v
- Recombinant Human Insulin inj. 10ml — 274.40 293.50
Insugen – 30/70 Vial
Insulin inj., Biphasic Iso., (Human
Insulin rDNA origin)
Isophane Insulin inj. ph. Euro., (70%)
Human Insulin ph. Eur., – 100 IU/ml
m-Cresol – 0.16% w/v
Phenol – 0.065% w/v
- Recombinant Human Insulin inj. 10ml — 274.46 293.56”
Insugen – N (NPH) Vial
Insulin inj., Biphasic Iso., (Human
Insulin rDNA origin)
Human Insulin ph. Eur., – 100 IU/ml
m-Cresol – 0.16% w/v
Phenol – 0.065% w/v
*Subject to actual payment of Government levies/taxes, as applicable.
Note :
(a) The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.
(b) The companies / manufacturers may added taxes only if they have paid actually to the Government on the price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
(c) For different packing material used or, different drug delivery systems or any other special features/forms claimed, the retail prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
(d) The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
(e) These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.
(f) These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
(g) The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.
(h) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor of 1.0696 as per the existing rates of excise duty and VAT.
(i) The MRP arrived as above shall be subject to payment of Government levies / taxes as applicable and necessary adjustment in the factor of 1.0696 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.0696. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.
PN/114/2010/F
F. No. 8(23)/2010/D.P./NPPA-Div.-II
(MANISH GOSWAMI)
Deputy Director
Last Page Updated: 03-06-2019
Copyright © 2023 - All Rights Reserved- Official Website of National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Government of India
Note :Website Content Managed by National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Designed, Developed and Hosted by National Informatics Centre Services Inc.(NICSI)